Long-term Patient and Health Service Outcomes of Ablation and Antiarrhythmic Drugs in Atrial Fibrillation: A Comparative Systematic Review.
Journal
Cardiology in review
ISSN: 1538-4683
Titre abrégé: Cardiol Rev
Pays: United States
ID NLM: 9304686
Informations de publication
Date de publication:
21 Nov 2022
21 Nov 2022
Historique:
entrez:
2
2
2023
pubmed:
3
2
2023
medline:
3
2
2023
Statut:
aheadofprint
Résumé
Atrial fibrillation (AF) is a prevalent problem worldwide and a common cause of hospitalization, poor quality of life, and increased mortality. Although several treatments are used, the use of ablation and antiarrhythmic drug therapy has increased in the past decade. However, debate continues on the most suitable option for heart rhythm control in patients. Previous studies have largely focused on short-term outcome effects of these treatments. This systematic review aims to determine the effect of ablation compared to antiarrhythmic drugs for AF on long-term patient and health service outcomes of mortality, hospitalization, and quality of life. Three databases were systematically searched-studies were included if they reported long-term outcomes of more than 12 months comparing the 2 treatments. Title and abstract screening and subsequent full-text screening was done by 2 reviewers. Data were extracted from the final studies identified. The details of the search were recorded according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses report. A total of 2224 records were identified. After removing duplicates and screening the titles and abstracts, 68 records required full-text screening. Finally, 12 papers were included in the analysis. Eight studies reported mortality indicating ablation was superior, 2 studies reported hospitalization with opposing outcomes, and 5 quality of life studies indicating ablation was a better treatment. In studies assessing long-term outcomes, beyond 12 months, following ablation or rhythm control drugs for AF, most found a lower risk of death and greater improvement in quality of life in the ablation group.
Identifiants
pubmed: 36730485
doi: 10.1097/CRD.0000000000000493
pii: 00045415-990000000-00040
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure: The authors declare no conflict of interest.
Références
Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129:837–847.
Colilla S, Crow A, Petkun W, et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the US adult population. Am J Cardiol. 2013;112:1142–1147.
Zoni-Berisso M, Lercari F, Carazza T, et al. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol. 2014;6:213–220.
Ball J, Thompson DR, Ski CF, et al. Estimating the current and future prevalence of atrial fibrillation in the Australian adult population. Med J Aust. 2015;202:32–35.
Wong CX, Brown A, Tse H-F, et al. Epidemiology of atrial fibrillation: the Australian and Asia-Pacific perspective. Heart Lung Circ. 2017;26:870–879.
AIHW. Atrial fibrillation in Australia [Internet]. 2020. Available at: https://www.aihw.gov.au/reports/heart-stroke-vascular-diseases/atrial-fibrillation-in-australia/contents/impact. Accessed September 30, 2021
Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013;34:2746–2751.
Lee E, Choi E-K, Han K-D, et al. Mortality and causes of death in patients with atrial fibrillation: a nationwide population-based study. PLoS One. 2018;13:e0209687e0209687.
Patel NJ, Deshmukh A, Pant S, et al. Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 through 2010: implications for healthcare planning. Circulation. 2014;129:2371–2379.
Bhat A, Khanna S, Chen HH, et al. Drivers of hospitalization in atrial fibrillation: A contemporary review. Heart Rhythm. 2020;17:1991–1999.
Epstein AE, Slabaugh J, Barnard D, et al. Quality of life in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J. 2005;149:112–120.
Thrall G, Lane D, Carroll D, et al. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med. 2006;119:448.e1–448.e19
Blomström-Lundqvist C, Gizurarson S, Schwieler J, et al. Effect of catheter ablation vs antiarrhythmic medication on quality of life in patients with atrial fibrillation: the CAPTAF randomized clinical trial. J Am Med Assoc. 2019;321:1059–1068.
Prystowsky EN, Padanilam BJ, Fogel RI. Treatment of atrial fibrillation. J Am Med Assoc. 2015;314:278–288.
Middeldorp ME, Ariyaratnam J, Lau D, et al. Lifestyle modifications for treatment of atrial fibrillation. Heart. 2020;106:325–332.
Bunch TJ, Crandall BG, Weiss JP, et al. Patients treated with catheter ablation for atrial fibrillation have long‐term rates of death, stroke, and dementia similar to patients without atrial fibrillation. J Cardiovasc Electrophysiol. 2011;22:839–845.
Kumar K, Zimetbaum PJ. Antiarrhythmic drugs 2013: state of the art. Curr Cardiol Rep. 2013;15:410.
Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. J Am Med Assoc. 2005;293:2634–2640.
Verma A, Natale A. Why atrial fibrillation ablation should be considered first-line therapy for some patients. Circulation. 2005;112:1214–22; discussion 1231.
Tanner H, Makowski K, Roten L, et al. Catheter ablation of atrial fibrillation as first-line therapy—a single-centre experience. Europace. 2011;13:646–653.
Nielsen JC, Johannessen A, Raatikainen P, et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N Engl J Med. 2012;367:1587–1595.
Freeman JV, Tabada GH, Reynolds K, et al. Comparison of long-term adverse outcomes in patients with atrial fibrillation having ablation versus antiarrhythmic medications. Am J Cardiol. 2020;125:553–561.
Blandino A, Toso E, Scaglione M, et al. Long‐term efficacy and safety of two different rhythm control strategies in elderly patients with symptomatic persistent atrial fibrillation. J Cardiovasc Electrophysiol. 2013;24:731–738.
Mont L, Bisbal F, Hernández-Madrid A, et al.; SARA investigators. Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study). Eur Heart J. 2014;35:501–507.
Freeman JV, Shrader P, Pieper KS, et al. Outcomes and anticoagulation use after catheter ablation for atrial fibrillation. Cir Arrhythm Electrophysiol. 2019;12:e007612.
Sang CH, Chen K, Pang XF, et al. Depression, anxiety, and quality of life after catheter ablation in patients with paroxysmal atrial fibrillation. Clin Cardiol. 2013;36:40–45.
Hunter RJ, Berriman TJ, Diab I, et al. A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial). Cir Arrhythm Electrophysiol. 2014;7:31–38.
Poole JE, Bahnson TD, Monahan KH, et al.; CABANA Investigators and ECG Rhythm Core Lab. Recurrence of atrial fibrillation after catheter ablation or antiarrhythmic drug therapy in the CABANA trial. J Am Coll Cardiol. 2020;75:3105–3118.
Kriatselis C, Kaufmann J, Nedios S, et al. Fast atrial activity predicts recurrence of atrial fibrillation after pulmonary vein isolation: results from a prospective randomized study. J Interv Card Electrophysiol. 2015;42:101–106.
Asad ZUA, Yousif A, Khan MS, Al-Khatib SM, Stavrakis S. Catheter ablation versus medical therapy for atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. Cir Arrhythm Electrophysiol. 2019;12:e007414.
Allan KS, Aves T, Henry S, et al. Health-related quality of life in patients with atrial fibrillation treated with catheter ablation or antiarrhythmic drug therapy: a systematic review and meta-analysis. Can J Cardiol Open. 2020;2:286–295.
Khan SU, Rahman H, Talluri S, et al. The clinical benefits and mortality reduction associated with catheter ablation in subjects with atrial fibrillation: a systematic review and meta-analysis. JACC Clin Electrophysiol. 2018;4:626–635.
Zhu M, Zhou X, Cai H, et al. Catheter ablation versus medical rate control for persistent atrial fibrillation in patients with heart failure: a PRISMA-compliant systematic review and meta-analysis of randomized controlled trials. Medicine. 2016;95:e4377.
Kularatna S, Sharma P, Senanayake S, et al. The effect of ablation compared to antiarrhythmic drugs for atrial fibrillation for long-term patient and health service outcomes: A systematic review. PROSPERO. 2021; CRD42021266606 Available at: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021266606
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J. 2021;10:1–11.
Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons; 2019.
WebPlotDigitizer version 4.5 [Internet]. 2021. Available at: https://automeris.io/WebPlotDigitizer/. Accessed April 12, 2021
Drevon D, Fursa SR, Malcolm AL. Intercoder reliability and validity of WebPlotDigitizer in extracting graphed data. Behav Modif. 2017;41:323–339.
Sterne JA, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. Br Med J. 2019;366:l4898.
Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. Br Med J. 2016;355:i4919.
Di Biase L, Mohanty P, Mohanty S, et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. Circulation. 2016;133:1637–1644.
Hunter RJ, McCready J, Diab I, et al. Maintenance of sinus rhythm with an ablation strategy in patients with atrial fibrillation is associated with a lower risk of stroke and death. Heart. 2012;98:48–53.
Jarman JW, Hussain W, Wong T, et al. Resource use and clinical outcomes in patients with atrial fibrillation with ablation versus antiarrhythmic drug treatment. BMC Cardiovasc Disord. 2018;18:1–9.
Lin Y-J, Chao T-F, Tsao H-M, et al. Successful catheter ablation reduces the risk of cardiovascular events in atrial fibrillation patients with CHA2DS2-VASc risk score of 1 and higher. Europace. 2013;15:676–684.
Yang PS, Sung JH, Jang E, et al. Catheter ablation improves mortality and other outcomes in real‐world patients with atrial fibrillation. J Am Heart Assoc. 2020;9:e015740.
Wang H, Du X, Guo L, et al. Ablation versus medical therapy for atrial fibrillation in the elderly: a propensity score-matched comparison. Med Sci Monit. 2019;25:9875.
Pappone C, Vicedomini G, Augello G, et al. Radiofrequency catheter ablation and antiarrhythmic drug therapy: a prospective, randomized, 4-year follow-up trial: the APAF study. Cir Arrhythm Electrophysiol. 2011;4:808–814.
Wu G, Huang H, Cai L, et al. Long-term observation of catheter ablation vs. pharmacotherapy in the management of persistent and long-standing persistent atrial fibrillation (CAPA study). EP Europace. 2021;23:731–739.
Zhang X-D, Gu J, Jiang W-F, et al. Optimal rhythm-control strategy for recurrent atrial tachycardia after catheter ablation of persistent atrial fibrillation: a randomized clinical trial. Eur Heart J. 2014;35:1327–1334.
Padanilam BJ, Prystowsky EN. Should atrial fibrillation ablation be considered first-line therapy for some patients? Should ablation be first-line therapy and for whom? the antagonist position. Circulation. 2005;112:1223–1229. discussion 30.
Cappato R, Calkins H, Chen S-A, et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation. 2005;111:1100–1105.
Ngo L, Ali A, Ganesan A, et al. Ten-year trends in mortality and complications following catheter ablation of atrial fibrillation. Eur Heart J Qual Care Clin Outcomes. 2022;8:398–408.
Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the american college of cardiology/american heart association task force on practice guidelines and the european society of cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): Developed in collaboration with the european heart rhythm association and the heart rhythm society. Circulation. 2006;114:e257–e354.
Andrade JG, Wells GA, Deyell MW, et al. Cryoablation or drug therapy for initial treatment of atrial fibrillation. N Engl J Med. 2021;384:305–315.
Mansour M, Heist EK, Agarwal R, et al. Stroke and cardiovascular events after ablation or antiarrhythmic drugs for treatment of patients with atrial fibrillation. Am J Cardiol. 2018;121:1192–1199.
Jones DG, Haldar SK, Hussain W, et al. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. J Am Coll Cardiol. 2013;61:1894–1903.
Chong E, Chang H-Y, Chen Y-Y, et al. When atrial fibrillation co-exists with coronary artery disease in patients with prior coronary intervention-Does ablation benefit? Heart Lung Circ. 2016;25:538–550.
Packer DL, Mark DB, Robb RA, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. J Am Med Assoc. 2019;321:1261–1274.
Reynolds MR, Gunnarsson CL, Hunter TD, et al. Health outcomes with catheter ablation or antiarrhythmic drug therapy in atrial fibrillation: results of a propensity-matched analysis. Circ Cardiovasc Qual Outcomes. 2012;5:171–181.
Long S, Xi Y, Gao L, et al. Safety and efficacy of catheter ablation in atrial fibrillation patients with left ventricular dysfunction. Clin Cardiol. 2020;43:305–314.
Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018;378:417–427.
Mark DB, Anstrom KJ, Sheng S, et al. Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial. J Am Med Assoc. 2019;321:1275–1285.
Emery J, Boyle D. Data linkage. Aust Fam Physician. 2017;46:615–619.
Wong IK, Grulich AE, Poynten IM, et al. Time trends in cancer incidence in Australian people living with HIV between 1982 and 2012. HIV Med. 2022;23:134–145.
Gallacher PJ, McAllister DA, Mills NL, et al. Infective endocarditis hospitalizations and outcomes in patients with end‐stage kidney disease: a nationwide data‐linkage study. J Am Heart Assoc. 2021;10:e022002.
Yoon Y, Deighton J, Wickersham A, et al. The role of mental health symptomology and quality of life in predicting referrals to special child and adolescent mental health services. BMC Psychiatry. 2021;21:1–8.
Briffa T, Hung J, Knuiman M, et al. Trends in incidence and prevalence of hospitalization for atrial fibrillation and associated mortality in Western Australia, 1995–2010. Int J Cardiol. 2016;208:19–25.
Weber C, Hung J, Hickling S, et al. Drivers of hospitalisation trends for non-valvular atrial fibrillation in Western Australia, 2000–2013. Int J Cardiol. 2019;276:273–277.